Telesis Bio appoints William Kullback as CFO effective August 28, 2023

Telesis Bio Inc.

Kullback's base salary set at $430,000 with target bonus of 50% of salary and $100,000 signing bonus.
Company will recommend a grant of an option to purchase 300,000 shares of common stock.
Previously CFO at BioLegend, where he led its $5.25B sale to Revvity (PerkinElmer).
Kullback also served as CFO at Lombard Medical (Nasdaq: EVAR) from 2014 to 2017.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

William Kullback

Chief Financial Officer

Telesis Bio Inc.

Effective: 2023-08-28
Filed: August 29, 2023, 7:59 PM ET

On August 28, 2023, the Company appointed William Kullback, age 63, as Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

William Kullback was appointed as Chief Financial Officer at Telesis Bio Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On August 28, 2023, the Company appointed William Kullback, age 63, as Chief Financial Officer.

View on SEC.gov

Source: SEC EDGAR

accession 0001193125-23-223802

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.